The estimated Net Worth of Thomas Phd Adams is at least $233 Tausend dollars as of 14 May 2020. Thomas Adams owns over 13,986 units of Hepion Pharmaceuticals Inc stock worth over $14,156 and over the last 21 years he sold HEPA stock worth over $157,248. In addition, he makes $61,967 as Independent Director at Hepion Pharmaceuticals Inc.
Thomas has made over 5 trades of the Hepion Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 13,986 units of HEPA stock worth $20,000 on 14 May 2020.
The largest trade he's ever made was exercising 100,023 units of Hepion Pharmaceuticals Inc stock on 3 July 2018 worth over $50,012. On average, Thomas trades about 4,959 units every 77 days since 2003. As of 14 May 2020 he still owns at least 18,875 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Thomas Adams stock trades at the bottom of the page.
Dr. Thomas H. Adams Jr., Ph.D. serves as Independent Director of the Company. Dr. Adams has been Chief Executive Officer of Cardiff Oncology, Inc., a clinical-stage oncology therapeutics company, since June 2018 and Chairman of the Board since April 2009. Dr. Adams has served as the Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, since April 2013. From June 2005 through 2011, Dr. Adams served as a director of IRIS International, Inc., a diagnostics company, and has served as Chief Technology Officer of IRIS since April 2006. Dr. Adams was the Head of Iris Molecular Diagnostics from 2006 until November 2012 and has served as the President of Iris Personalized Medicine since 2011. In November 2012, IRIS was acquired by Danaher Corporation. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to April 2006, when Leucadia was acquired by IRIS. In 1989, Dr. Adams founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. Dr. Adams founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams has served as a director of Synergy Pharmaceuticals Inc., a biotechnology company, since July 2009. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, at Riverside. The Board believes that Dr. Adams’ executive leadership, particularly in the diagnostic field, and the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a director of our Company.
As the Independent Director of Hepion Pharmaceuticals Inc, the total compensation of Thomas Adams at Hepion Pharmaceuticals Inc is $61,967. There are 8 executives at Hepion Pharmaceuticals Inc getting paid more, with Robert Foster having the highest compensation of $621,102.
Thomas Adams is 77, he's been the Independent Director of Hepion Pharmaceuticals Inc since 2016. There are no older and 11 younger executives at Hepion Pharmaceuticals Inc.
Thomas's mailing address filed with the SEC is C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121.
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over $0 worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth $247,400 . The most active insiders traders include Gary S Jacob, Peter Wijngaard und John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of $7,481. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth $15,350.
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: